Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Cloppenburg – page 8

191 clinical trials in Cloppenburg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Cloppenburg at a glance
191
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

191 trials in Cloppenburg

Open in trial search

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:GPOH gGmbH

Acute myeloid leukaemia+1

Not yet recruiting

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:GPOH gGmbH

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Alumis Inc.

Hidradenitis

Not recruiting

Evaluation of CIT-013 at two dose levels compared to placebo for treating moderate to severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:CIT-013
  • Sponsor:Citryll B.V.

Psoriasis

Not recruiting

Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

Hidradenitis

Not recruiting

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Study on IMVT-1402 for Patients with Active Cutaneous Lupus Erythematosus

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Neuralgia+1

Not recruiting

Study on LY3848575 for Reducing Pain in Patients with Distal Sensory Polyneuropathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3848575
  • Sponsor:Eli Lilly & Co.

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Psoriasis

Not recruiting

Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Envudeucitinib
  • Sponsor:Alumis Inc.

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of JNJ-95475939 and Dupilumab for Treating Moderate to Severe Atopic Dermatitis in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Janssen Cilag International

Psoriasis

Not recruiting

Study on Long-term Safety and Effectiveness of Zasocitinib for Patients with Moderate-to-Severe Plaque Psoriasis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Cloppenburg

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on hyperlipoproteinemia and cardiovascular disease management through advanced therapeutic approaches. Research evaluates long-term safety and effectiveness of treatments for patients requiring lipoprotein apheresis.

  • Lipid Management
  • Cardiovascular Disease Prevention
  • Therapeutic Safety Assessment

These trials aim to improve treatment options for patients with elevated lipoprotein levels and established cardiovascular conditions.

02 Nephrology Studies

Groundbreaking research investigating treatments for IgA Nephropathy, focusing on preventing progressive loss of renal function. The studies evaluate novel therapeutic approaches for managing proteinuria in affected patients.

  • Renal Function Protection
  • Proteinuria Management
  • Disease Progression Prevention

Clinical investigations aim to advance treatment options for patients with kidney disorders through targeted therapeutic approaches.

03 Treatment Optimization

Comprehensive evaluation of therapeutic interventions across multiple medical conditions, with a focus on long-term safety profiles and treatment effectiveness. Studies include both controlled trials and extension phases.

  • Long-term Safety Monitoring
  • Treatment Tolerability
  • Patient Outcomes Assessment

Research efforts are directed at optimizing treatment protocols and improving patient care standards.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.